Blogs | MedChemExpress

Alobresib is an Orally Active BET Bromodomain Inhibitor for Uterine Serous Carcinoma Treatment

Alobresib is a novel and potent BET bromodomain inhibitor for recurrent/chemotherapy resistant uterine serous carcinoma overexpressing c-Myc.
MT-802 is a PROTAC Degrader of BTK for C481S Mutant CLL Treatment

MT-802 is a potent BTK degrader based on PROTAC technology, with a DC50 of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia.
GSK3368715 is an Orally Active Type I PRMT Inhibitor

GSK3368715 is an orally active and SAM uncompetitive type I PRMT inhibitor that produces a shift in arginine methylation states.
MBM-55 is a Potent Nek2 Inhibitor for Cancer Therapy

MBM-55 is a potent, selective Nek2 inhibitor with an IC50 of 1 nM. MBM-55 shows antitumor activities and induces cell cycle arrest and apoptosis.
APG-115, an Orally Active MDM2 Inhibitor, Induces Cell-Cycle Arrest and Apoptosis in a p53-Dependent Manner

APG-115 is an orally active MDM2 protein inhibitor binding to MDM2 protein. APG-115 blocks the interaction of MDM2 and p53 and induces apoptosis.
M-89, a Specific Menin inhibitor, Has Potential to Treat MLL Leukemia

M-89 is a specific menin inhibitor, with a Kd of 1.4 nM. M-89 inhibits the Menin-MLL protein-protein interaction and has potential to treat MLL leukemia.
GSK2643943A is a Novel DUB Inhibitor

GSK2643943A is a novel deubiquitylating enzyme (DUB) inhibitor. GSK2643943A targets USP20/Ub-Rho and shows an IC50 of 160 nM.
FGTI-2734, a Dual FTase and GGTase Inhibitor, Has Potential to Treat KRAS-mutant Cancer

FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
SAR-260301 is an Orally Active PI3Kβ Inhibitor for Melanoma Treatment

SAR-260301 is a selective PI3Kβ inhibitor with an IC50 of 23 nM. SAR-260301 is a potent and highly selective PI3Kβ inhibitor for melanoma.
dBET6, an Orally Active PROTAC Degrader of BET, Has Potential to Treat ALL

dBET6 is a potent PROTAC degrader of BET, shows high affinity to BRD4(1), and possess good efficacy in T cell acute lymphoblastic leukemia activity.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (31)